As expected, the FDA has moved quickly to grant emergency use authorisation (EUA) to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicr
The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.
Pfizer is aiming to be first on the grid in the race to being a vaccine against respiratory syncytial virus (RSV) to market, after reporting results from a phase 3 trial of the jab in older
Jack Torrance, investment specialist for Baillie Gifford's Health Innovation Fund, tells us how the organisation ensures its investments will have the most significant positive impact on al
The UK's Joint Committee on Vaccinations and Immunisations (JCVI) has said that Moderna's bivalent COVID-19 vaccine should be used for the autumn booster campaign in adults.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl